OrbiMed Capital GP VII LLC
CIK 1760648 · last filed 2025-12-18
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$239.66M
Companies
11
Total Filings
31
Lifetime Open-Market Net
$225.95M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| KROS | Director | 45,057 | $10.07 | $453.7K | $18.01M | 2 | 2025-12-18 |
| PASG | 10%+ Owner | 313,980 | $4.57 | $1.43M | $17.76M | 13 | 2025-06-26 |
| MBX | Director | 3,205,930 | $60.06 | $192.55M | $6.06M | 1 | 2025-02-19 |
| Theseus Pharmaceuticals, Inc. (THRX) Delisted | Director | 0 | $4.06 | $0 | $7.74M | 3 | 2024-02-14 |
| Damora Therapeutics, Inc. (GLTO) Delisted | Director | 36,571 | $28.69 | $1.05M | $52.66M | 2 | 2023-07-17 |
| Kinnate Biopharma Inc. (KNTE) Delisted | Director | 794,368 | $2.65 | $2.11M | $70.72M | 2 | 2023-05-02 |
| Terns Pharmaceuticals, Inc. (TERN) Delisted | Director | 762,400 | $52.95 | $40.37M | $5.00M | 1 | 2022-12-28 |
| Sierra Oncology, Inc. (SRRA) Delisted | Director | 226,704 | $54.99 | $12.47M | $0 | 1 | 2022-01-28 |
| JANX | Director | 2,403,566 | $15.00 | $36.05M | -$22.50M | 1 | 2021-12-17 |
| Repare Therapeutics Inc. (RPTX) Delisted | Director | 97,293 | $2.65 | $257.8K | $40.50M | 3 | 2021-09-02 |
| IMRA | Director | 633,100 | $14.49 | $9.17M | $30.00M | 1 | 2021-07-16 |
Recent Filings · Page 3 of 4
31 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-01-21 | Theseus Pharmaceuticals, Inc. (THRX) Delisted | Buy (P) | +475,251 | $4.74M | EDGAR |
| 2022-01-13 | PASG | Buy (P) | +300,000 | $1.68M | EDGAR |
| 2021-12-17 | JANX | Sell (S) | −1,179,900 | -$22.50M | EDGAR |
| 2021-09-02 | Repare Therapeutics Inc. (RPTX) Delisted | Sell (S) | −113,592 | -$3.87M | EDGAR |
| 2021-08-19 | Repare Therapeutics Inc. (RPTX) Delisted | Sell (S) | −60,984 | -$2.08M | EDGAR |
| 2021-07-16 | IMRA | Buy (P) | +4,999,998 | $30.00M | EDGAR |
| 2020-12-04 | Kinnate Biopharma Inc. (KNTE) Delisted | Buy (P) | +2,250,000 | $45.00M | EDGAR |
| 2020-11-04 | Damora Therapeutics, Inc. (GLTO) Delisted | Mixed | +19,016,275 | $55.00M | EDGAR |
| 2020-06-25 | Repare Therapeutics Inc. (RPTX) Delisted | Mixed | +10,126,575 | $46.45M | EDGAR |
| 2020-04-13 | KROS | Mixed | +3,806,202 | $18.01M | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.